Related by context. All words. (Click for frequent words.) 63 excludes noncash 61 pretax 60 noncash charge 60 nonrecurring 59 goodwill impairment 59 noncash accounting 59 noncash goodwill 58 Noncash 58 intangible assets impairment 58 asset impairment 58 aftertax 57 noncash goodwill impairment 57 intangible impairment 57 non recurring 57 goodwill impairment charge 57 nonrecurring items 57 LIFO inventory valuation 57 compensation expense 56 intangibles impairment 56 LIFO accounting 56 impairment charges 55 Excluding discontinued operations 55 debt extinguishment 55 Adjusted EBITDA excludes 55 debt extinguishments 55 noncash impairments 55 pension curtailment 55 impairment charge 55 postretirement benefit 54 noncash impairment charge 54 profitsharing 54 noncash impairment 54 amortization expense 54 pretax goodwill impairment 54 intangible asset impairments 54 nonoperating 54 noncash pretax 54 amortizable intangible assets 54 valuation adjustments 54 Visa indemnification 54 nonrecurring expenses 54 aftertax charge 53 amortization 53 goodwill impairments 53 exclude noncash 53 unrealized derivative losses 53 Excluding goodwill impairment 53 unamortized deferred 53 pretax noncash 52 nonoperating items 52 unrealized derivative 52 Surface Specialties acquisition 52 unrealized hedging 52 remeasurement 52 Equinix excludes 52 d Represents 52 nonroutine income 52 FAS #R 52 write offs 52 f Represents 52 Pro forma adjustments 52 uncollectible accounts receivable 52 intangible asset 52 early extinguishment 52 Impairment Charge 51 LIFO adjustments 51 expensing 51 unconsolidated investee 51 asset impairments 51 OREO valuation 51 SFAS No. 51 nondeductible 51 aftertax gain 50 OTTI charges 50 unabsorbed fixed manufacturing 50 Adjusted OIBDA excludes 50 intangible impairments 50 preopening expenses 50 forecasts typically exclude 50 hedge ineffectiveness 50 DAC unlock 50 asset impairments restructuring 50 No. #R 50 misdated stock 50 noncash amortization 50 unrealized losses 50 Unizan merger 50 unamortized financing 50 excluding goodwill impairment 50 adopting SFAS #R 50 netincome 50 c Consists 50 unamortized issuance costs 50 Restructuring impairment 50 c Excludes 50 unrealized derivative gains 50 Estimates typically exclude 50 MSR hedging 50 depreciation amortization impairment 50 identifiable intangible assets 50 accelerated depreciation 49 discontinued operations 49 Excluding 49 intangible assets 49 option expensing 49 nonoperating income 49 j Includes 49 mainline CASM excluding 49 depreciation amortization 49 unallocated expenses 49 unfavorable variance 49 severance accruals 49 stock basedcompensation 49 IAROC 49 intangible amortization 49 depreciation depletion amortization 49 unamortized 49 excludes depreciation 49 loss NOL carryforward 49 expensed 49 NOL utilization 49 goodwill writedown 49 early extinguishments 49 No. #R SFAS 49 foreign currency remeasurement 49 Nonrecurring 49 unrealized gain 49 LIFO inventory 49 INOVA Geophysical 49 depreciation noncash 49 Supervalu 3Q 49 unrealized gains 48 temporary impairment OTTI 48 unrealized appreciation 48 impacting comparability 48 c Includes 48 OTTI 48 NOL carryforwards 48 SFAS 48 unamortized debt 48 identifiable intangible 48 unallocated corporate 48 derivative liabilities 48 excluding nonrecurring 48 FDIC indemnification 48 currency remeasurement 48 pretax noncash charges 48 b Excludes 48 BlackRock MLIM transaction 48 FASB Statement #R 48 narrows 4th qtr 48 c Represents 48 depreciable assets 48 FHLMC preferred stock 48 inventories revalued 48 depletion depreciation 48 b Represents 48 f Reflects 48 Acquired Intangible Assets 48 Qualcomm Strategic Initiatives 48 uncollectible accounts 48 adopted SFAS #R 48 b Reflects 48 write downs 48 Statement #R 48 DAC unlocking 48 purchased intangible assets 48 accelerated vesting 48 FASB #R 48 temporary impairments OTTI 47 unamortized portion 47 severance outplacement 47 Excludes amortization 47 unvested restricted stock 47 accretion expense 47 noncash intangible 47 MFB Corp 47 acquired intangibles 47 Excluding nonrecurring items 47 Business.com Acquisition 47 identifiable intangibles 47 items affecting comparability 47 exchangeable debentures 47 accrual reversal 47 modified coinsurance 47 pretax writedowns 47 LIFO adjustment 47 excludes depreciation amortization 47 temporary impairments 47 SunPower incurs amortization 47 unamortized deferred financing 47 discount accretion 47 SFAS #R 47 postretirement expense 47 goodwill intangible 47 excluding 47 GSCT program 47 Timeshare segment 47 AMF Ultra Short 47 excludes 47 nonoperating expense 47 MSR valuation 46 depreciation accretion 46 FAS CAS pension 46 commodity derivative instruments 46 Visa MasterCard antitrust 46 fuel CASM 46 noncash writedown 46 noncash pretax impairment 46 excludes unrealized gains 46 Adjustments Restructuring 46 DiaMed acquisition 46 excluding unrealized derivative 46 noncash pretax charge 46 MA PFFS 46 lease terminations 46 taxes depreciation amortization 46 No. #R Share 46 accrual reversals 46 acquired intangible assets 46 noncontrolling interest 46 c Relates 46 nonvested 46 nonoperating expenses 46 FAS #R Share 46 noncash unrealized 46 - -Labyer 46 amortizable 46 CASM excluding fuel 46 LIFO reserve 46 operatingincome 46 Expensing 46 non gaap 46 Other Income Expense 46 Goodwill Impairment 46 Non recurring 46 FDIC indemnification asset 46 OSIs 46 Adjusted EBITDAX 46 Consolidated EBITDAR 46 Harland Clarke tradename 46 misdating 46 intangibles amortization 46 antidilutive 46 d Reflects 46 FAS #R expense 46 LIFO 46 - Adjusted [028] 46 Adjusted EBT 46 affecting comparability 46 adopting FAS #R 46 TWACS NG software 46 deductible goodwill impairment 45 asset write downs 45 b Includes 45 unamortized discount 45 Analysts typically exclude 45 inventory write downs 45 Based Compensation 45 continuingoperations 45 APB# 45 Including discontinued operations 45 asset valuation allowance 45 ASC #-# 45 -Josephine Marcotty 45 restatement 45 postretirement benefit plans 45 MSR impairment 45 writedown 45 redeemable preferred stock 45 mandatorily redeemable preferred 45 AOCL 45 Payment FAS #R 45 Significant Items 45 diluted share 45 equity investee 45 Copano commodity 45 JasmineSola brand 45 noninterest expense decreased 45 modestly dilutive 45 incurs amortization 45 LAST YEAR 'S QUARTER 45 retrospectively adjusted 45 Current Installments 45 LPT Agreement 45 - - Earnunderwent resection 45 OTTI charge 45 Goodwill impairment 45 Introductory teaser rates 45 unrealized depreciation 45 MDS Proteomics 45 marketable securities 45 unvested 45 non capitalizable 45 Accretion expense 45 contingently convertible debt 45 g Represents 45 postretirement benefit expense 45 Mainline CASM excluding 45 impairment 45 - - Net [003] 45 OPEB expense 45 Compensation Expense 45 Non GAAP Adjusted EBITDA 45 posts 4th qtr 45 unrealized gains losses 45 FSP APB #-# 45 SchoolHouse division 45 -lipid nanoparticles 45 unrealized derivative gain 45 noncontrolling interests 45 Debt extinguishments 45 typically exclude special 44 Restructuring Charge 44 posts 2Q 44 SurfControl deferred revenue 44 DAC offsets 44 postemployment benefits 44 EITF #-# [001] 44 Deduct 44 TEB adjustment 44 derivative instruments 44 addback 44 accruals 44 estimates typically exclude 44 accrual 44 Excludes depreciation 44 goodwill writeoff 44 nonGAAP 44 loss carryforward 44 Non GAAP Diluted EPS 44 dilutive securities 44 intercompany balances 44 NON CASH EXPENSES 44 unvested options 44 contractual minimums 44 expenses 44 narrows 3Q loss 44 currency translations 44 carryforwards 44 excluding depreciation amortization 44 #R Share Based 44 -Angelo Nieves 44 FAS CAS Pension 44 deferred compensation 44 noncurrent assets 44 unrealized 44 accretable 44 Amortiza tion 44 accretion DD & 44 depreciation amortization depletion 44 Brooks Eckerd drugstore chain 44 equity accounted investees 44 posts 4Q 44 NETg acquisition 44 doubtful accounts receivable 44 misdated options 44 Noninterest expense decreased 44 - -Belusko 44 Nasdaq LCAPA 44 Normalised earnings 44 reasonably estimable 44 contingently convertible securities 44 FIFO inventory 44 Excluding nonrecurring 44 CIC convertible debenture 44 Based Compensation Expense 44 dilutive effect 44 purchased intangibles 44 -Ivgi 44 PMPS brand 44 narrows 3Q 44 c Reflects 44 CASM decreased 44 Contingent consideration 44 ASC Topic #-# 44 Unrealized derivative 44 posts 1st qtr 44 Consolidated Entities 44 intersegment revenues 44 Unusual Items section 44 deconsolidation 44 FAS# R 44 - Non GAAP [021] 44 narrows 4Q loss 44 depreciation amortization accretion 44 -Senanu 44 Intangibles amortization 44 - Non GAAP [001] 44 per dilutedshare 44 - - Net [047] 44 goodwill amortization 43 translation adjustment 43 SFAS# R 43 junior subordinated debentures 43 unvested stock 43 cents ashare 43 nondeductible expenses 43 retroactive reinstatement 43 postretirement 43 - - [054] 43 Intangible amortization 43 Debt extinguishment costs 43 Impairment Charges 43 excluding depreciation depletion 43 b Relates 43 SEK -#.# -#.# [003] 43 trims 1Q 43 EBITDAO 43 underwriting discounts commissions 43 valuation allowance 43 FASB Interpretation No. 43 adopting SFAS 43 operating loss carryforwards 43 hefty goodwill impairment 43 infrequently occurring 43 Expensing options 43 FAS#R 43 Currency fluctuation 43 compensation accruals 43 -triseries 43 adjusted EBITDAR 43 #.#/diluted share 43 NextRx subsidiary 43 dilutive antidilutive effects 43 refranchising transactions 43 invoiced shipment 43 Hedge ineffectiveness 43 depreciation 43 asset impairments severance 43 severance 43 loss carryforwards 43 Inventory obsolescence 43 - Adjusted [022] 43 - Adjusted [009] 43 posts 3Q 43 OREO write downs 43 Debt Extinguishment 43 noncurrent liabilities 43 narrows 2Q 43 receivable balances 43 Reconciling Items 43 valuation allowances 43 Posts Wider 1Q 43 Individual Annuities segment 43 MtM gains 43 Asset Retirement Obligations 43 equity method investees 43 excludes amortization 43 LIFO liquidation 43 Than Temporary Impairments 43 MDP Transaction 43 non cancelable lease 43 Compensation Expenses 43 dacetuzumab collaboration 43 Accelerated depreciation 43 Tax Expense 43 Adjusted EPS 43 EBITDAS EBITDA 43 Pro forma EPS 43 undepreciated assets 43 AOCI 43 Than Temporary Impairment 43 Unallocated Corporate 43 charitable deductions 43 Consolidated OIBDA 43 hedging derivative instruments 43 Filtran Microcircuits Inc. 43 Write downs 43 nonmarketable 43 undepreciated 43 Asset impairment 43 accretable yield 43 adopted SFAS 43 Exterran stockholders 43 adjusted EBITDAS 43 - Adjusted [015] 43 Business Combinations 43 noninterest expense 43 - - Non GAAP [001] 43 FSAH Acquisition 43 Lease termination 43 FNMA preferred 43 Widens 1Q 43 SFSB transaction 43 unamortised 43 Noninterest expenses 42 Currency translation 42 - - Non GAAP [006] 42 accounts receivable balances 42 Alcott Routon intangible assets 42 Asset Impairment 42 - Adjusted [006] 42 taxes EBDDT 42 loan chargeoffs 42 - - NET INCOME [002] 42 currency translation 42 Posts 3Q Loss 42 Noncurrent deferred income 42 shutdowns asset impairments 42 - - Non GAAP [007] 42 Restructuring asset impairments 42 Adjusted OIBDA 42 uncollectable receivables 42 noninterest expenses 42 nondividend distribution 42 restatements 42 nondeductible portion 42 amortization #,#,# 42 Mainline CASM 42 QSI segment certain 42 Impairments 42 Partially offset 42 b Excluded 42 Unitholder distributions 42 Reported Unaudited Condensed 42 adopting FIN 42 LAE reserves 42 postretirement benefit OPEB 42 - Adjusted [010] 42 earnings 42 BlackRock LTIP shares 42 Bois d' Arc's 42 Astaris joint venture 42 Hesperion acquisition 42 Curtailment gain 42 - - [019] 42 INTEGRA LIFESCIENCES HOLDINGS CORPORATION 42 intercompany eliminations 42 Noncash compensation 42 enhances comparability 42 excluding unrealized gains 42 Valuation allowance 42 Synthetic Fuel 42 - - [045] 42 Drivetrain segment 42 Deductions depreciation 42 standardized distributable cash 42 nonequity incentives 42 Discontinued Operation 42 deconsolidating 42 Unvested 42 hedging instruments 42 OTTI write downs 42 SFAS No.# 42 capitalizable 42 consolidated balance sheet 42 DNOI 42 SFAS #R Share 42 Earnout 42 nonconsolidated affiliate 42 NOLs 42 cents 42 Posts Wider 2Q 42 intercompany loans 42 intersegment transactions 42 Interest Expense Interest expense 42 #R Share 42 Certain Unusual Items 42 reclass 42 equity investees 42 defeased loans 42 #.#per diluted 42 - - NetMarigot Bay r 42 millioncompared 42 - Adjusted [025] 42 Embedded Derivatives 42 retrying Blagojevich 42 unconsolidated subsidiaries 42 Core FFO 42 Asset impairments 42 Company noncontributory defined 42 preferred dividends 42 Discretionary cash 42 diluted EPS 42 typically exclude 42 administrative expenses 42 Expenses 42 - Non GAAP [015] 42 -Celine Dion Eric Clapton 42 restate financials 42 - -Frode Johnsen 42 uncollectible receivables 42 Unrealized gains 42 dis synergies 42 divestitures 42 itemized charitable 42 Mayne Pharma intangible assets 42 establishing valuation allowance 42 impairments 42 Adjusted Earnings 42 Mortgage Servicing Rights 41 Impairment 41 COHT 41 Depreciation Amortization Taxes 41 Excludes unrealized 41 Spin Off Costs 41 prorations 41 Qimonda Infineon 41 #.# perdiluted 41 Remeasurement 41 posts 1Q 41 Veraz excludes 41 nonqualifying hedges 41 Restructuring 41 nonroutine 41 - Adjusted EBITDA [001] 41 FSP EITF #-#-# [002] 41 Variable Interest Entities VIEs 41 - SegmentPrincess Dina Mired 41 ATSG subsidiaries include 41 Pharmacia Monsanto 41 noncumulative perpetual preferred 41 ASM excluding 41 Treasurer Elaine Lintecum 41 Amortization Expense 41 Ps.#.# [002] 41 Recurring FFO 41 Restructuring Charges 41 MSEK -# [002] 41 pro forma adjusted EBITDA 41 FSP EITF #-#-# [001] 41 Adjusted diluted 41 deferred loan origination 41 Adjusted EBITDA 41 FSP #-# 41 Real Estate Owned OREO 41 nonvested stock 41 IREX joint venture 41 ended September# 41 SFSB Inc. 41 Section #/#K 41 Interest expense net 41 LIFO expense 41 - Non GAAP [027] 41 timberland disposals net 41 deferred 41 depreciable asset 41 - - Non arachnophobes 41 Adjusted Gross Profit 41 undernoted items 41 Oilseeds Processing 41 restructuring 41 Interest Income Expense 41 deemed uncollectible 41 earnings pershare 41 FQ = fiscal 41 makes RoundUp herbicide 41 Unlevered Cash Flow 41 DJO Merger 41 No. #R FAS 41 - -OSCAR WINNING 41 asset writedowns 41 contingently convertible 41 NewMil 41 - AdjusETON 41 Brooks Eckerd drugstores 41 accumulated undistributed 41 Nonoperating 41 Avantome Inc. 41 Charitable donations 41 Allscripts excludes 41 Positively impacting 41 Posts Wider 4Q Loss 41 consolidated PRASM 41 Promotions.com subsidiary 41 Oxy ER 41 FAS CAS 41 actuarially determined 41 Pro forma net 41 Amortization 41 mile CASM excluding 41 TransFirst LLC 41 amortization OIBA 41 Efficiency ratio excluding 41 Contingent Value Right 41 unfavorable variances 41 Merger Related 41 acquisitions divestitures transfers 41 millionin 41 NSF OD 41 mainline CASM 41 cardmember spending 41 j Represents 41 Concur excludes 41 income 41 nontaxable 41 Impairment Losses 41 Posts Narrower 4Q Loss 41 Inc. OTC CDCO 41 Net income 41 LIFO inventory accounting 41 CASM excluding 41 FHLB advances decreased 41 NOL carryforward 41 Inventory writedown 41 Non GAAP adjusted EBITDA 41 Reports 4Q Loss 41 adjusted OIBDA 41 Incurred losses 41 intersegment eliminations 41 nausea superficial edema 41 -killing Alan Shalleck 41 Posts 2Q Loss 41 Xantic acquisition 41 expire unexercised 41 amortization# 41 Convertible Debt 41 GVIC consolidated debt 41 owned OREO 41 Unearned compensation restricted 41 - Adjusted EBITDA [002] 41 uncollectible reinsurance 41 charitable contributions 41 unallocated ESOP shares 41 Petrojarl Varg FPSO 41 Adjusted 41 unconsolidated investments 41 - - Earnings [004] 41 Debt extinguishment 41 - Adjusted [012] 41 Movado boutiques 41 loss carrybacks 41 disqualifying dispositions 41 Iridesse subsidiary 41 unconsolidated investees 41 calculating distributable cash 41 Accounts receivables 41 - Loss [013] 41 - - Income [031] 41 2Q Loss Widens 41 depletable 41 Cheneys owed 41 improperly backdated 41 carrybacks 41 - Non GAAP [009] 41 Valeant stockholders 41 Asset Retirement Obligation 41 Excluding Unusual Items 41 reinsurance recoverable 41 Euro denominated intercompany 41 Filmyard Holdings LLC 41 Segment Margin 41 adjusted EBITDA 41 Olefins Polyolefins 41 Items excluded 41 - - Net [035] 41 realizability 41 LOCOM adjustment 41 Crisa acquisition 41 SLM commonly 41 EMEA Subsidiaries 41 4Q Loss Widens 41 incentive accruals 41 Medicare Advantage PFFS 41 Chubb repurchased 41 QSI segment 41 noninterest expense partially offset 41 Excludes goodwill 41 Adjusted EBITDAS 41 EBIAT 41 credit carryforwards 41 perpetual debentures 41 nonconvertible debt borrowing 41 = Basic [035] 41 Amortized cost 41 DPAC amortization 41 securitized Timeshare notes 41 Novogyne 41 investees partially offset 41 reconciles Adjusted EBITDA 41 reestimates 41 Narrows 3Q 40 IAC Evite 40 flow hedges 40 unproved acreage 40 Hedging Relationships 40 revenues excluding nonrecurring 40 Adjustments Inventory 40 - Adjusted [030] 40 depreciation depletion 40 Yiyang Yukang 40 - - [084] 40 Accelerated vesting 40 pretax writedown 40 noninterest income 40 Melania Timepieces & 40 Therics 40 Add subtract 40 excludes acquisitions divestitures 40 SFAS No.#R 40 OREO properties 40 Leveraged Lease 40 unexercised options 40 QSI SG & 40 Vacation accrual 40 Adjusted EBTIDA 40 unbooked resource potential 40 - - IncoLawrence Schiffman 40 Nasdaq LINTA LINTB 40 Derivative Instruments 40 - - Net [055] 40 Pretax 40 Senior Exchangeable Notes 40 AutoZone repurchased 40 Timberland disposals net 40 Octane Additives 40 Pro forma EBITDA 40 Unallocated corporate 40 QSBS 40 FSP FAS #-# 40 reissuances 40 postretirement obligations 40 posts 3rd qtr 40 Reclassifications 40 undesignated hedges 40 - Adjusted [019] 40 Clarica brand 40 distort comparability 40 - Total noninterest expense 40 FRBNY Facility 40 Unrealized foreign 40 sale leaseback transactions 40 prepaids 40 reportable segment 40 depreciable real estate 40 Files Amended Plan 40 PRE TAX OPERATING EARNINGS 40 cash 40 AWP litigation 40 non GAAP 40 postretirement benefits 40 PTOI 40 Medicare Advantage premiums 40 warrants expired unexercised 40 FunTees 40 overallotment provision 40 #.#/BOE [002] 40 inventory obsolescence 40 Ps.#.# [007] 40 liabilities #,#,# [001] 40 business acquired VOBA 40 Expects 2Q 40 writeoffs 40 Amortiz 40 - Non GAAP [004] 40 SECURITY SYSTEMS LTD 40 Settles Shareholder Lawsuit 40 MAGNETIX 40 income teb 40 Unallocated expenses 40 SFAS#R 40 - Non Shane Germann 40 Adjusted Pro Forma 40 Embraer RJ 40 mildly dilutive 40 intercompany receivables 40 Containerboard Packaging 40 Noninterest Expense Noninterest expense 40 DSUs 40 Extraordinary Item 40 Scantron segments 40 Depreciation Amortization 40 Huarun minority interest 40 allowable deductions 40 - - Net [051] 40 Unusual Items 40 QUALCOMM pro forma 40 Purchased intangible assets 40 Reports Wider 40 Innovis Entities 40 QUALCOMM Strategic Initiatives 40 Position APB #-# 40 CICA Handbook Section 40 - - Income [029] 40 Adjusted Diluted EPS 40 unabsorbed manufacturing 40 Accelerated Depreciation 40 - Adjusted [016] 40 principal paydowns 40 client reimbursables 40 lump sum distributions 40 non amortizing intangible 40 - Non GAAP [028] 40 Reclassification adjustment 40 Munger reimbursed 40 mostly nonbranded 40 unevaluated properties 40 - - Net [041] 40 repricings 40 Accrued severance 40 Backdating involves manipulating 40 MSR valuation adjustments 40 3Q Loss Widens 40 reinsurance recoverables 40 1Q Loss 40 derivative instrument 40 Acquisition Related 40 EITF #-# [002] 40 Domestic Car Rental 40 Diluted FFO 40 Fingerhut catalog 40 SigmaKalon acquisition 40 - Adjusted [013] 40 Early Extinguishment 40 Goodwill impairment charge 40 strategic alliances divestitures 40 - Segment [005] 40 SEK -# 40 fiscal# 40 Nonrecurring items 40 Tikcro holdings 40 Interest expense 40 operating income1 40 net realizable 40 Concateno plc 40 Narrows 1Q 40 = Non GAAP [005] 40 - Non GAAP [023] 40 Och Ziff Operating 40 spokesman Terry Balluck 40 asset dispositions 40 VIEs 40 Expense 40 AMPAC ISP Holdings 40 visit www.radioshack.com 40 CICA Handbook section 40 MEP Joint Venture 40 = ReconciliIsilon IQ delivers 40 4th qtr profit 40 posts 2nd qtr 40 adjusted distributable cash 40 adjusted EDITDA 40 - - Adjusted EBITDA [001] 40 RRSP contribution room 40 - - Net [033] 40 unvested restricted 40 condensed consolidated balance sheets 40 repurchases 40 Posts 4Q Loss 40 Annual Incentive Plan 40 - Total noninterest [010] 40 NOI SS NOI 40 LIFO inventory reserve 40 GAAP EPS 40 deducting underwriting commissions 40 Extends 40 Omnicef inventory 40 Republish without 40 - Loss [020] 40 EnPro consolidated 40 #,# -Ehie 40 invoiced shipments 40 - - Total [037] 40 Negatively impacting 40 Realized gains 40 Vyvx advertising 40 #,# -BOB SANSEVERE 40 Noncurrent 40 - Non GAAP [007] 40 Items affecting comparability 40 includable 40 obj obj = 40 Intangibles Goodwill 40 Derivative Liabilities 40 - Adjusted [008] 40 derivative contracts 40 Mortgage loan originations 40 EURO#.# [002] 40 Polymer Additives segment 40 Derivative Liability 40 Nonregulated 40 ATCF 40 Economic Stimulus Rebate 40 Accounting Principle 40 SS NOI 40 narrows 1Q loss 40 writeoff 40 3Q 40 Arana Therapeutics Limited 40 Iceland Latvia Lithuania 40 - Adjusted EBITDA [006] 40 NAREIT FFO 40 earnigns 40 FFO Per Share 40 unredeemed gift cards 40 - Loss [010] 40 adjusted OIBDA margin 39 earnout payments 39 QSPEs 39 overfunded pension 39 Q4 Profit Plummets 39 pershare 39 - Adjusted [011] 39 Accrued restructuring 39 exclude nonrecurring items 39 FASB Statement No. 39 applied prospectively 39 4Q FY#